ข้ามไปยังเนื้อหา 
In regulated manufacturing industries, digital recordkeeping are no longer simple files used to store data. They have become traceable sources of evidence.
สำหรับเภสัชกรรม, โภชนเภสัช, medical device, and contract manufacturing companies, electronic records and electronic signatures are essential for ensuring production safety, maintaining quality assurance, and preventing costly disruptions caused by formulation changes or process parameter adjustments. As U.S. regulations have evolved, 21 ส่วนซีเอฟอาร์ 11 compliance has gradually become a mandatory requirement rather than an optional investment.
For many manufacturers, especially small and medium-sized companies, implementing system validation and compliant data management solutions can seem expensive and complex. ส่งผลให้, two key questions are often raised first: when did 21 ส่วนซีเอฟอาร์ 11 go into effect, and what is 21 ส่วนซีเอฟอาร์ 11 การปฏิบัติตาม?
This comprehensive guide offers 21 ส่วนซีเอฟอาร์ 11 explained in detail. We will explore what is 21 ส่วนซีเอฟอาร์ 11, who needs to comply with it, its key requirements, and how to achieve 21 ส่วนซีเอฟอาร์ 11 compliance in a practical and cost-effective way.
ประเด็นสำคัญ
- When did 21 ส่วนซีเอฟอาร์ 11 go into effect and its historical context.
- คืออะไร 21 ส่วนซีเอฟอาร์ 11 in pharmaceutical industry.
- Who needs 21 ส่วนซีเอฟอาร์ 11 compliance across various industries.
- Core 21 ส่วนซีเอฟอาร์ 11 requirements for records, signatures, access, and audit trails.
- How to comply with 21 ส่วนซีเอฟอาร์ 11 step by step.
- How Part 11 compliant equipment supports pharmaceutical and nutraceutical production.
1. When Did 21 ส่วนซีเอฟอาร์ 11 Go Into Effect?
According to the FDA’s official website, 21 ส่วนซีเอฟอาร์ 11 went into effect on August 20, 1997.
What prompted the issuance of this regulation? Its origins lie in the major transition from paper-based records to computerized systems. Previously, pharmaceutical production records, laboratory reports, and quality documents were largely created, signed, and stored on paper. As production scales expanded, simple paper records could no longer meet the need for rapid documentation and immediate data retrieval, leading companies to adopt digital systems.
To ensure the reliability of these new systems, ที่ 21 code of federal regulations part 11 links 21 ซีเอฟอาร์ 11 electronic records electronic signatures to strict regulatory oversight. When companies use digital data to support decisions subject to FDA regulation, that data must be accurate and secure, as well as traceable and retrievable during FDA inspections.
2. คืออะไร 21 ส่วนซีเอฟอาร์ 11?
Definition Of 21 ส่วนซีเอฟอาร์ 11
ที่แกนกลางของมัน, what is 21 ส่วนซีเอฟอาร์ 11? It is a regulation established by the U.S. FDA that dictates how to manage electronic records signatures.
To understand 21 ส่วนซีเอฟอาร์ 11 regulations, consider the FDA’s historical oversight of locked filing cabinets, monitoring who managed them and tracking who opened or modified their contents. As these filing cabinets have evolved into digital systems, the FDA has introduced these 21 ส่วนซีเอฟอาร์ 11 guidelines to ensure the systems are properly controlled and the data remains secure.
What Types Of Records Are Covered?
21 ส่วนซีเอฟอาร์ 11 electronic records may include:
- Electronic batch records
- Manufacturing records
- Quality control records
- Equipment operation logs
- Laboratory test results
- Cleaning and maintenance records
- Training records
- Change control and deviation records
It should be noted that this regulation does not apply to all digital files; it applies only when electronic records are used to meet FDA record-keeping requirements.
Which Industries Must Comply?
Compliance requirements under 21 ส่วนซีเอฟอาร์ 11 may apply to a wide range of entities, including pharmaceutical, dietary supplement, and medical device manufacturers, as well as contract manufacturing organizations, testing laboratories, and companies exporting FDA-regulated products to the United States.
เพราะเหตุนี้, questions such as “Does 21 ส่วนซีเอฟอาร์ 11 apply to medical devices?” และ “What does 21 ส่วนซีเอฟอาร์ 11 cover?” are critical; the core principle governing the rule’s applicability is that compliance requirements are triggered whenever electronic systems are used to support records or approvals subject to FDA data integrity requirements.
3. Why Was 21 ส่วนซีเอฟอาร์ 11 Introduced?
21 ส่วนซีเอฟอาร์ 11 was introduced because digital manufacturing created both new efficiency and new compliance risks.
21 ส่วนซีเอฟอาร์ 11 emerged in response to the efficiency gains and new compliance risks associated with digital manufacturing. As the industry transitioned from paper-based records to digital systems, the FDA needed to establish regulations ensuring the reliability of electronic records; this rule applies to FDA-regulated records that are created, modified, maintained, archived, retrieved, or transmitted electronically.
The core objective of the rule is to safeguard 21 ส่วนซีเอฟอาร์ 11 data integrity and prevent tampering or falsification by requiring systems to feature audit trails, acting much like a “black box” that records the true sequence of events. During FDA inspections, regulators examine electronic batch records, part 11 audit trail requirements, user access controls, และ 21 ส่วนซีเอฟอาร์ 11 compliant electronic signatures; these comprehensive historical records serve as the cornerstone for regulatory compliance, คุณภาพของผลิตภัณฑ์, and customer trust.
4. Who Needs 21 ส่วนซีเอฟอาร์ 11 การปฏิบัติตาม?
Not every company needs the same level of control, but many FDA regulated manufacturers should evaluate who needs 21 ส่วนซีเอฟอาร์ 11 compliance based on their systems and market.
Drug Manufacturers
สำหรับ 21 ส่วนซีเอฟอาร์ 11 pharmaceutical industry, electronic record systems involving batch information, การควบคุมคุณภาพ, equipment logs, or release approvals are generally required to comply with 21 ส่วนซีเอฟอาร์ 11. อย่างไรก็ตาม, once electronic records formally replace paper records, this compliance obligation becomes mandatory rather than optional.
Dietary Supplement Manufacturers
If a dietary supplement manufacturer processes production, คุณภาพ, or batch records electronically and the product is intended for sale in the United States, the CFR Part 11 compliance are likely to apply.
Medical Device Manufacturers
For those asking does 21 ส่วนซีเอฟอาร์ 11 apply to medical devices, the answer is yes when electronic records support FDA quality system requirements.
Contract Manufacturing Organizations
CMOs often need strong FDA CFR Part 11 compliance because they serve multiple clients and face frequent customer audits.
Companies Exporting To The United States
Even if the manufacturer is located outside the United States, compliance with Part 11 requirements is generally still required provided the products are sold in the U.S. and the electronic records pertain to FDA-regulated activities.
5. คืออะไร 21 ส่วนซีเอฟอาร์ 11 Requirements?
ดี, according to the document, what exactly are the 21 ส่วนซีเอฟอาร์ 11 requirements? The answer can be grouped into several practical controls. Compliance requirements under 21 ส่วนซีเอฟอาร์ 11 center on five key areas: electronic records, electronic signatures, เส้นทางการตรวจสอบ, user access controls, and record retention and retrieval.
บันทึกอิเล็กทรอนิกส์
21 ส่วนซีเอฟอาร์ 11 requirements for electronic records state that electronic records must be accurate, complete, ปลอดภัย, readable, and retrievable. Companies should maintain proper record retention and secure data storage.
ลายเซ็นอิเล็กทรอนิกส์
FDA part 11 electronic signatures must clearly establish identity and accountability, displaying the signer’s name, the timestamp, and the meaning of the action (เช่น, “approval for release”) to ensure they hold the same legal validity as handwritten signatures.
Audit Trails
How audit trail works in pharmaceutical equipment is a common question. Audit trails automatically record all critical actions, including creation, modification, deletion, approval, and system changes, to ensure traceability. If a batch’s weight data is changed from 500 kg to 510 กิโลกรัม, the audit log records the modifier, the time of the change, and the values before and after the edit, facilitating root cause analysis.
User Access Controls
Access controls ensure that only authorized personnel can perform specific actions through password protection and permission management, utilizing multi-factor authentication and the principle of least privilege.
Record Retention And Retrieval
Records must remain readily accessible throughout the FDA-mandated retention period; failure to retrieve data promptly during an audit is considered a serious compliance violation.
6. How To Comply With 21 ส่วนซีเอฟอาร์ 11
Achieving compliance is a primary concern for most pharmaceutical and health product companies. In this section, we will explore the subject in depth, covering specific implementation steps, potential issues, and corresponding solutions.
ขั้นตอน 1 – Conduct A 21 ส่วนซีเอฟอาร์ 11 Compliance Assessment
You should start by comparing all systems that create, modify, เก็บ, retrieve, or transmit FDA-regulated electronic records against 21 ส่วนซีเอฟอาร์ 11 guidelines for pharmaceuticals. The assessment should include validation, audit trail, การควบคุมการเข้าถึงของผู้ใช้, electronic signatures, record retention, and security.
Follow the 21 ซีเอฟอาร์ 11 compliance checklist can speed up your process.
ขั้นตอน 2 – Validate Computerized Systems
ก 21 ส่วนซีเอฟอาร์ 11 compliant system should go through validation to prove they perform as intended. ในทางปฏิบัติ, validation should be carried out as a structured sequence of actions:
1. Define and Assess System Scope and Risk
Start by clearly documenting what the system is supposed to do and identify where the risk is. ตัวอย่างเช่น, อัน เครื่องบรรจุแคปซูล must record fill weight, ความเร็ว, และหมายเลขแบทช์.
2. Test and Verify System Performance
ต่อไป, perform structured testing using IQ, โอคิว, and PQ. This assesment is to check if the system is working as expected.
3. Document, Approve, and Maintain Control
ในที่สุด, all validation activities must be documented, reviewed, and approved before system release.
ขั้นตอน 3 – Implement Audit Trail Functionality
You need to ensure the integrity of the audit trail function, confirming that the system securely stores and records data, such as timestamps and changes, and allows for accurate retrieval. Take the adjustment of capsule filling machine parameters as an example: once an operator modifies the filling parameters, the system automatically captures the old and new values, the operator ID, and the timestamp.
ขั้นตอน 4 – Establish Electronic Signature Controls
To meet electronic signatures FDA expectations, each user should have a unique identity. Electronic signatures should be linked to specific records and should not be copied or reassigned.
ขั้นตอน 5 – Control User Access
Use role-based access. Different roles should have different permisssions. For adminisstrators, they always have the superior permissions, while operators only have partial permissions.
7. Ruida Packing Machinery: Providing FDA And GMP Compliant Machines
Somtimes even if manufactrers are willing to equip their machines with audit trail system, not all machines support it. Ruida Packing, collaborating with well-known pharmaceutical companies, including UCB and US Pharma, undoubtedly is commited to develop part 11 compliant equipment. Our machines are supported by CE, CGMP, ไอเอสโอ, and related certificates. According to clients needs, Ruida can also provide 21 ส่วนซีเอฟอาร์ 11 monitoring solution for production and packaging equipment.
Ruida also supports pharmaceutical manufacturing with practical service details:
- Certified materials: 304 stainless steel for non-contact parts and 316L stainless steel for contact parts.
- Remote and on-site commissioning services, with after-sales centers in North America and Hong Kong.
- สมบูรณ์ machine guidance: Manuals, operation guidance, maintenance documents, and after-sales videos.
- ไอคิว, โอคิว, PQ Documentation: Optional support for validation documents, IQ OQ PQ, and compliance documentation.
For manufacturers planning 21 ส่วนซีเอฟอาร์ 11 การปฏิบัติตาม, choosing equipment with compliance-ready options can reduce future modification costs and make audits easier to prepare for.
8. บทสรุป
Looking back at when did 21 ส่วนซีเอฟอาร์ 11 go into effect, we can see how profoundly it has shaped the industry since 1997. Sicne August 20 in the year, this regulation has been a standard how FDA regulated companies should manage electronic data. ทุกวันนี้, 21 ส่วนซีเอฟอาร์ 11 compliance has been a focus and concern for many pharma and nutra manufacturers, and you’d better off preparing for it. Not just the validation, but also the machines.
9. คำถามที่พบบ่อย
ไตรมาสที่ 1: Is 21 ส่วนซีเอฟอาร์ 11 Mandatory?
ใช่, of course. But it not suits for all electronic recording systems. It is mandatory when electronic records or electronic signatures are used to meet FDA requirements.
คิว2: Where the GMP And 21 CFR Part 11’s Difference Lies in?
ดี, they have different focus. GMP focuses on product quality, ในขณะที่ 21 ส่วนซีเอฟอาร์ 11 focuses on electronic records and electronic signatures.
คิว3: Does Every Pharmaceutical Machine Need Part 11 การปฏิบัติตาม?
เลขที่. A machine needs Part 11 consideration when it creates, stores, modifies, or transmits regulated electronic records. Purely mechanical equipment may not need the same level of control.
คิว4: What Is An Audit Trail?
An audit trail is to record any actions done on the system, showing the exact action, เวลา, and any changes.
คิว5: How Do I Know If Equipment Supports Part 11 Requirements?
You can check whether it supports audit trails, การควบคุมการเข้าถึงของผู้ใช้, electronic signatures, secure data storage, record export, and validation documents. But put it simlpe, just go ask the machine suppliers before purchase.
Refจrences
[1] เรา. สำนักงานคณะกรรมการอาหารและยา: ส่วนหนึ่ง 11, บันทึกอิเล็กทรอนิกส์; Electronic Signatures — Scope and Application
[2] รหัสอิเล็กทรอนิกส์ของกฎระเบียบของรัฐบาลกลาง: 21 ส่วนซีเอฟอาร์ 11 — Electronic Records; ลายเซ็นอิเล็กทรอนิกส์[3] Federal Register: บันทึกอิเล็กทรอนิกส์; Electronic Signatures Final Rule, Published March 20, 1997
[3] Federal Register: บันทึกอิเล็กทรอนิกส์; Electronic Signatures Final Rule, Published March 20, 1997
